Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score–Matched Controlled Prospective Study
Abstract
Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very few treatments have improved progression-free survival (PFS) in advanced CTCL, and no treatment has increased overall survival (OS). In 2023, the results of the CUTALLO trial supported the hypothesis that hematopoietic stem-cell transplantation (HSCT) was associated with significantly longer PFS as compared with standard-of-care treatment among advanced-stage patients although HSCT did not significantly affect OS. We provide herein the final OS data pertaining to the same patient population after a longer median follow-up of 38.9 months. Of the 99 patients included in the analysis, 55 (56%) were assigned to the HSCT group, whereas 44 (44%) were allocated to the non-HSCT group. The updated survival analysis reported that 16 of 55 patients (29%) in the HSCT group and 22 of 44 patients (50%) in the non-HSCT group died. The median OS was not reached in the HSCT group and 51.5 months (95% CI, 26.9 to 51.5) in the non-HSCT group (hazard ratio, 0.40 [95% CI, 0.20 to 0.80]). Compared with the standard of care for advanced CTCL, after extended follow-up, allogeneic HSCT was associated with significantly longer OS.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (52)
Adele De Masson
Pierre Fabre Medicament, Paris, France
Marie Beylot-Barry
Department of Dermatology, INSERM Unité 1312, Centre Hospitalier Universitaire (CHU) and Université de Bordeaux, Bordeaux, France
Caroline Ram-Wolff
Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France
Jean-Baptiste Mear
13University Hospital of Rennes, Clinical hematology, Rennes, France
Stéphane Dalle
Jacques Rouanet
Department of Dermatology, CHU de Clermont-Ferrand, Clermont-Ferrand, France
Saskia Ingen-Housz-Oro
Department of Dermatology, AP-HP, Hôpital Henri Mondor, University Paris-Est Créteil, Créteil, France
Corentin Orvain
8CHU d'Angers, Hematology, Angers, France
Julie Abraham
31Service Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire de Limoges–Hôpital Dupuytren, Limoges, France
Olivier Dereure
Department of Dermatology, University of Montpellier, Montpellier, France
Amandine Charbonnier
6CHU AMIENS, AMIENS, France
Jerome Cornillon
6Centre Hospitalier Universitaire de Saint-Etienne, Service d’Hématologie Clinique, Saint-Priest-en-Jarez, France
Christine Longvert
Department of Dermatology, CHU Ambroise Paré, AP-HP, Boulogne-Billancourt, France
Stéphane Barete
22Unit of Dermatology Reference Centre for Mastocytosis (CEREMAST) AP-HP, Pitié-Salpêtrière Hospital, Paris, France
Serge Boulinguez
Department of Dermatology, CHU de Toulouse, Toulouse, France
Ewa Wierzbicka-Hainaut
Department of Dermatology, CHU de Poitiers, Poitiers, France
François Aubin
Groupe Infectiologie et Infections Sexuellement Transmissibles (GrIDIST) of the French Society of Dermatology, Paris
Marie-Thérèse Rubio
25CHU de Nancy – Hôpital de Brabois, Nancy, France
Marc Bernard
17CHU, Renne, France
Aline Schmidt-Tanguy
Department of Hematology, CHU d’Angers, Angers, France
Roch Houot
21Service d’Hématologie, Centre Hospitalier Universitaire Pontchaillou, Rennes, France
Anne Pham-Ledard
1Université de Bordeaux, UMR 1312, Bordeaux, France
David Michonneau
Hélène Labussière-Wallet
3Hospices Civils de Lyon - CHU Lyon Sud, Hematologie Clinique, Pierre-Bénite, France
Jean-David Bouaziz
Florent Grange
CH de Valence, Valence, France
Hélène Moins-Teisserenc
Université Paris Cité, Paris, France
Katayoun Jondeau
Department of Hematology, CHU Ambroise Paré, AP-HP, Boulogne-Billancourt, France
Samia Mourah
INSERM U1342 Institut de Recherche Saint-Louis, Paris, France
Maxime Battistella
5Assistance Publique des Hôpitaux de Paris (APHP), Hôpital Saint Louis, Service d'anatomopathologie, Paris, France
Etienne Daguindau
Michael Loschi
12Centre Hospitalier Universitaire de Nice, Nice, France
Alexandra Picard
Department of Dermatology, CHU de Nice, Nice, France
Nathalie Franck
Department of Dermatology, Hôpital Cochin, AP-HP, Paris, France
Natacha Maillard
26Poitiers university hospital Poitiers, Hematology unit, Poitiers, France
Anne Huynh
5Department of Hematology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
Stéphanie Nguyen
Department of Hematology, CHU Pitié-Salpêtrière, AP-HP, Paris, France
Ambroise Marcais
Guillaume Chaby
Center of Evidence of the French Society of Dermatology, Paris
Patrice Ceballos
5Centre Hospitalier Universitaire Hôpital Saint Eloi, Service d'hématologie, Montpellier, France
Yannick Le Corre
Department of Dermatology, CHU d’Angers, Angers, France
Sébastien Maury
12Service d’Hématologie Clinique, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Paris, France
Jacques-Olivier Bay
5CHU Estaing, Thérapie Cellulaire et Hématologie Clinique, Clermont Ferrand, France
Henri Adamski
Department of Dermatology, Hôpital Pontchaillou, CHU de Rennes, Rennes, France
Emmanuel Bachy
Edouard Forcade
Gerard Socie
Hematology Transplantation, Assistance Publique–Hôpitaux de Paris, Hospital Saint Louis, Paris, France
Martine Bagot
4Hôpital Saint Louis, APHP, Inserm U976, Université Paris Cité, Paris, France
Sylvie Chevret
Régis Peffault de Latour
Pauline Brice
Laurence Michel